Oscare to exhibit ultrasound-based method for osteoporosis assessment at Arab Health together with new distributor

Z1 International to distribute OsCare Sono™ in the Middle East

VANTAA, Finland — Oscare Medical Oy announces that it will be demonstrating its novel low frequency ultrasound device, the OsCare Sono™ for osteoporosis assessment, at this year’s Arab Health together with Z1 International, at stand Z4T01. Arab Health is the region’s largest medical exhibition and will be held on 26th – 29th January in Dubai, UAE.

A novel Quantitative ultrasound (QUS) device, the OsCare Sono™ assesses bone strength in the forearm radial bone. By using very low frequency ultrasound, the measurement results correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), including BMD of the deeper cortical layers – suggesting that the OsCare Sono™ offers enhanced sensitivity to early osteoporotic changes.

Founded in 2014, Z1 International is a new, energetic medical devices distributor company that covers the Middle East markets. Z1 General Manager Mohammad Zein commented: ”We are pleased to introduce the OsCare Sono™ to the Middle East markets. We believe there will be keen interest in an easy to use, non-invasive assessment device for this increasingly prevalent disease”. The International Osteoporosis Foundation (IOF), a non-profit, nongovernmental umbrella organization, considers osteoporosis a “neglected” disease in the Middle East. Demographic and socioeconomic changes in the region have contributed to the rise of this disease and its burden on the populations and healthcare systems. Furthermore, the IOF states that access to X-ray absorptiometry machines to measure bone mineral density is extremely limited (1). This emphasizes the importance of easily accessible screening methods.

About the OsCare Sono™

The OsCare Sono™ is a compact, hand-held device designed for use in clinics and low-threshold locations, such as high street pharmacies. The device offers a convenient way of assessing skeletal bone health and is a promising new screening tool for identifying people at an increased relative risk for osteoporosis and, potentially, bone fractures. A measurement is taken from the forearm over a few minutes using harmless ultrasound. Proprietary algorithms compensate for the effects of soft tissues. An individual’s measurement is compared to the normal value observed in healthy young women, and the final OsCare Sono™ result is ready within seconds for counseling.

About Oscare Medical

Oscare Medical was founded in 2007 to commercialize the results of a decade of research into bone health at the University of Jyväskylä, Finland. Since 2013, Oscare Medical has been majority-owned by Nasdaq-OMX-listed Revenio Group Corp and is now part of the Revenio Health Tech segment which includes the hugely successful Icare® tonometer product family. The OsCare Sono™ is CE-marked and available in multiple international markets. Oscare Medical is actively expanding its distribution partner network. See: www.oscaremedical.com.

Contact:
Mervi Turunen
Sales & Marketing Manager
Oscare Medical
T: +358 40 732 4904
mervi.turunen@oscaremedical.fi

Contact for Middle East sales:
Mohammad Zein
General Manager
Z1 International
Dubai Knowledge Village, Block 3
P.O. Box: 50221
Dubai, UAE
T: +971 4 453 990
Mobile: +971 55 865 4515
info@z1-international.com
www.z1-international.com

(1) THE MIDDLE EAST & AFRICA REGIONAL AUDIT, Epidemiology, costs & burden of osteoporosis in 2011, Executive Summary, Publisher: The International Osteoporosis Foundation

Oscare showcases its unique method for assessment of osteoporosis at Medica

Usefulness of OsCare Sono™ for assessment of osteoporosis validated in clinical studies

VANTAA, Finland – Oscare Medical Oy announces that it will be demonstrating its novel low frequency ultrasound device, the OsCare Sono™ for osteoporosis assessment, at this year’s Medica in Hall 16, booth E57. Medica, the world’s largest medical exhibition, will be held on 12th – 15th November in Dusseldorf, Germany.

Osteoporosis, a bone condition that incurs an increasing risk of fracture, is a rapidly increasing problem for aging societies. Recent studies have questioned the effectiveness of current screening guidelines and called for better early screening tools. X-ray-based methods are the gold-standard for confirming a diagnosis of osteoporosis, but the expense and the exposure to ionizing radiation mean X-ray techniques are impractical for community care. Quantitative ultrasound (QUS) methods are now generating renewed interest.

A novel QUS device, the OsCare Sono™ assesses bone strength in the forearm radial bone. By using very low frequency ultrasound, measurement results correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), including BMD of the deeper cortical layers – suggesting OsCare Sono™ offers enhanced sensitivity to early osteoporotic changes. The OsCare Sono™ device offers a convenient way of assessing skeletal bone health and is a promising new screening tool for identifying people at an increased relative risk for osteoporosis and, potentially, bone fractures.

About OsCare Sono™

The OsCare Sono™ is a compact, hand-held device designed for use in clinics and low-threshold locations, such as high street pharmacies. The device itself attaches via a USB connector to a standard PC. A measurement is taken from the forearm over a few minutes using harmless ultrasound. Proprietary algorithms compensate for the effects of soft tissues. An individual’s measurement is compared to the normal value observed in healthy young women, and the final OsCare Sono™ result is ready within seconds for counseling.

About Oscare Medical

Oscare Medical was founded in 2007 to commercialize the results of a decade of research into bone health at the University of Jyväskylä, Finland. Since 2013, Oscare Medical has been majority-owned by Nasdaq-OMX-listed Revenio Group Corp and is now part of the Revenio Health Tech segment which includes the hugely successful Icare® tonometer product family. The OsCare Sono™ is CE-marked and is already on sale in several European countries. Oscare Medical is now rapidly expanding its distribution partner network. See: www.oscaremedical.com.

Contact:

Mervi Turunen
Sales & Marketing Manager
T: +358 40 732 4904
mervi.turunen@oscaremedical.fi

OsCare Sono™ validated for osteoporosis screening in clinical studies

Two studies comparing the OsCare Sono™ measurement to central DXA measurements have recently been finalized. Given that central DXA measurement is considered the gold standard for diagnosis of osteoporosis, it is instructive to examine the association between OsCare Sono™ and DXA measurements and to determine the criteria needed to interpret OsCare Sono™ results.

In a large comparative study, measurements of bone strength using the OsCare Sono™ were compared to bone density measurements using a central DXA device. The study participants were 244 home-dwelling women, aged 70 – 80 years. The study was performed at the UKK Institute in Tampere, Finland. Another study comparing the OsCare Sono™ to DXA was performed at two osteoporosis clinics in Helsinki, Finland (Mehiläinen Oy’s Ympyrätalo and the Kätilöopisto Maternity Hospital), enrolling 75 subjects with average age of 67.

From the results of the validation studies it can be seen that with decreasing OsCare T-scores, the probability of being judged as healthy by DXA decreases and the probability of being diagnosed with osteoporosis increases. It can be recommended that all subjects with an OsCare T-score of less than -2.5 should be further investigated, as the risk for osteoporosis as diagnosed by DXA is great. For subjects with an OsCare T-score between -1 and -2.5, counseling on bone health should be given and further investigation considered – especially if there are other risk factors present that may con­tribute to osteoporosis.

Should you like to receive the technical white paper describing more in detail the results of the clinical validation studies, please send e-mail to mervi.turunen@oscaremedical.fi.

Today on world osteoporosis day, new survey reveals unawareness of men’s osteoporosis

A new survey by the International Osteoporosis Foundation (IOF) shows that on average, 90% of adults asked are unaware of how common osteoporotic fractures are in men. One in five men aged 50 years or more will suffer from osteoporotic fractures in their remaining lifetime. The survey data confirms that although osteoporosis is serious and potentially life-threatening, it remains largely neglected as a health issue. The multi-national survey was carried out in 13 258 men and women from 12 countries – ignorance was independent of gender or geography.

Oscare Medical’s easy method for osteoporosis screening enables recognizing those men and women who are at increased risk of osteoporosis. They can seek specialist attention and take preventive means into use. Better bone health will equal better life. “Real men build their strength from within” is the slogan of the World Osteoporosis Day which is celebrated today.

Visit us at Medica 2014

Oscare Medical will be presenting their unique solution for early osteoporosis assessment at Medica 2014 in Düsseldorf from 12th to 15th of November. Welcome to visit us in hall 16 booth E57, to learn more about the easy and reliable bone strength measurement and to get the strength of your bones assessed.

Oscare got great feedback from gynecologists

Oscare Medical’s easy bone health check drew a lot of attention in the ISUOG (International Society of Ultrasound in Obstetrics and Gynecology) conference held in Barcelona from the 14th to 17th of September. ISUOG is the leading event in women’s imaging and in dissemination of clinical guidance in the field of ultrasound in obstetrics and gynecology. Close to a hundred attendees were measured for their bone strength at the Oscare Medical booth.

The gynecologists who visited Oscare’s booth regarded the bone health check by OsCare Sono™ as fitting to their service offering very well and thought that their customers will show great interest to this convenient measurement providing important information on their bone health.

Oscare was granted a patent in Japan

The Japan patent office has granted Oscare Medical a patent titled “A method and a device for measuring density of a bone”, patent number 5592275. The term of patent protection is twenty years.

japanin patentti

Oscare presents at gynecology congress ISUOG in Barcelona from 14th to 17th of September

Oscare Medical will attend the International Society of Ultrasound in Obstetrics and Gynecology, ISUOG, conference in Barcelona, Spain, from the 14th to 17th of September 2014. Welcome to visit the Oscare booth to learn about Oscare’s effortless and reliable solution for osteoporosis screening! Bone health awareness is especially important for women, as they are at greater risk for osteoporosis than men, due to thinner and smaller bones and a sharp decrease of the bone protecting estrogen after menopause. It is estimated that over 200 million women have osteoporosis – more than the combined populations of Germany, UK and France.

http://www.isuog.org/WorldCongress/2014/

Oscare partners with Arbor Medical Korporacijal and Anpexim in distribution of its products in Latvia and Poland

Oscare Medical’s unique technology for easy, safe and reliable osteoporosis screening is now made available for customers in Latvia and Poland, as Oscare has agreed on sales partnership with Arbor Medica Korporacijal in Latvia and with Anpexim in Poland.

Arbor Medical Korporacijal is the leading medical technology sales and service company in Latvia having attracted the distributorship of several known international med tech companies such as Philips HealthCare. Since its foundation in 1995 Arbor Medical Korporacijal has grown into a company employing 50 people. Dace Rātfeldere, founding member and CEO of Arbor Medical Korporacijal said: “We are happy to expand our product portfolio with an innovative product such as OsCare Sono™. It fits with our mission to offer for our customers the best solutions and innovations available in the market place.”

Anpexim represents several known medical device manufacturers in Poland, including Merivaara, Allen Medical and Midmark. Since its foundation in 1993 Anpexim has established its place in the Polish healthcare industry as a respected company acknowledged for taking good care of its customers. Tomasz Stepniak, founding member and CEO of Anpexim, commented: “We are excited to start promoting OsCare Sono™ for our customers. It will make an attractive option for physicians and clinics who want to expand their offering to patients, allowing for the patients to easily get important information on the health of their bones.”

Mervi Turunen, sales and marketing manager for Oscare, said: “We are pleased to continue our growth with such experienced and successful partners as Arbor Medical and Anpexim, and have more patients benefit of the innovative Oscare technology for better bone health and better life.”

Through these partnerships Oscare continues its planned sales expansion in Europe, after having announced CE mark for its osteoporosis screening product last autumn.

Oscare was granted a patent in China

The State Intellectual Property Office of the P.R.C, SIPO, has granted Oscare Medical a patent titled “A method and a device for measuring density of a bone”, CN 101969846 B. The term of patent protection will be twenty years.